Exenatide
⚠️ Structural Separation Notice
The Ageless Pep Academy is a clinical education property independent from any commerce operation. Any references in this profile to Ageless Peps product SKUs, pricing, or the agelesspeps.com domain are for completeness and transparency; they are not endorsements and do not form part of the clinical education content. Clinicians are responsible for independent verification of any product sourcing decision. The Academy's Medical Director provides editorial oversight only and does not endorse commercial products.
Synthetic exendin-4 (Gila monster venom-derived), first-in-class GLP-1 receptor agonist; naturally resistant to DPP-4 degradation.
Quick Facts
| Property | Value |
|---|---|
| Also Known As | Byetta (IR), Bydureon (ER), Exendin-4, AC2993 |
| Category | GLP-1 Receptor Agonist (Metabolic) |
| Sequence | H-His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
| Molecular Weight | ~4186.6 Da |
| Molecular Formula | C184H282N50O60S |
| PubChem CID | 15991534 |
| Administration | SubQ (twice daily for Byetta; once weekly for Bydureon microsphere) |
| Typical Dose Range | 5-10 mcg BID (Byetta); 2 mg once weekly (Bydureon) |
| Half-Life | ~2.4 hours (Byetta IR); ~2 weeks effective release (Bydureon microsphere depot) |
| Storage | Refrigerate 2-8C; Byetta pens can be kept at room temperature for up to 30 days after first use |
| FDA Status | FDA Approved — Byetta (2005), Bydureon (2012) for type 2 diabetes |
| WADA Status | Not listed as prohibited |
Mechanism of Action
Exenatide is a synthetic 39-amino-acid peptide derived from exendin-4, a compound found in the saliva of the Gila monster lizard (Heloderma suspectum). It shares 53% amino acid sequence homology with native human GLP-1(7-36) but critically differs at position 2 (glycine vs. alanine), rendering it naturally resistant to dipeptidyl peptidase-4 (DPP-4) cleavage. This DPP-4 resistance gives exenatide a much longer half-life (~2.4 hours) compared to native GLP-1 (~2 minutes).
Exenatide binds to and activates the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed on pancreatic beta cells, the gastrointestinal tract, the central nervous system (hypothalamus, area postrema), and the cardiovascular system. Upon receptor activation, exenatide stimulates glucose-dependent insulin secretion via cAMP/PKA and Epac2 signaling pathways. Insulin release is amplified only when blood glucose is elevated, minimizing hypoglycemia risk.
Beyond insulin secretion, exenatide suppresses inappropriate glucagon release from pancreatic alpha cells (also glucose-dependent), slows gastric emptying to reduce the rate of postprandial glucose appearance, and promotes satiety through central hypothalamic signaling. These combined actions address multiple pathophysiological defects in type 2 diabetes simultaneously.
The extended-release formulation (Bydureon) uses poly(D,L-lactide-co-glycolide) (PLG) microsphere technology to create a subcutaneous depot that releases exenatide over approximately 10 weeks per injection, achieving steady-state plasma concentrations after 6-7 weeks of weekly dosing. This provides continuous GLP-1R activation, more akin to the long-acting agents (semaglutide, dulaglutide) than the pulsatile BID formulation.
Key Research Areas
- Type 2 Diabetes Glycemic Control — Exenatide consistently reduces HbA1c by ~1.0-1.6% with sustained effects over 5+ years (PMID: 25744115)
- Cardiovascular Outcomes — The EXSCEL trial (n=14,752) demonstrated CV safety with a trend toward benefit (HR 0.91 for MACE) (PMID: 28910237)
- Weight Management — Progressive weight loss of 1.0-3.0 kg observed across trials, distinguishing it from insulin therapy (PMID: 19719703)
- Beta-Cell Function — Evidence of improved beta-cell responsiveness and preservation of beta-cell mass in animal models
- Neuroprotection — Emerging research on exenatide for Parkinson's disease and other neurodegenerative conditions (based on GLP-1R expression in CNS)
Evidence Level Summary
| Evidence Type | Count | Notes |
|---|---|---|
| Human RCTs | 20+ | EXSCEL, DURATION 1-8, AWARD comparisons |
| Human observational | 10+ | Post-marketing surveillance, real-world studies |
| Animal in vivo | 15+ | Beta-cell preservation, neuroprotection models |
| In vitro | 5+ | GLP-1R signaling, beta-cell proliferation |
| Systematic reviews | 5+ | Efficacy/safety reviews, CV meta-analyses |
Clinical Applications
- Type 2 Diabetes — First-line injectable for glycemic control with weight-neutral-to-loss profile
- Weight Management — Modest weight loss (1-3 kg); not approved for obesity as standalone indication
- Metabolic Syndrome — Improvements in multiple cardiometabolic parameters
Protocols Using This Peptide
- Weight Loss Protocol — Referenced as comparator in GLP-1 RA landscape
- Metabolic Reset Protocol — May be used in GLP-1 RA-based metabolic optimization
Ageless Peps Products
Exenatide is an FDA-approved pharmaceutical (Byetta/Bydureon) and is NOT sold by Ageless Peps. It is included in this vault for educational reference and comparative understanding of the GLP-1 RA landscape.
Dosing Reference
FDA-Approved Dosing
| Route | Dose Range | Frequency | Duration | Source |
|---|---|---|---|---|
| SubQ (Byetta) | 5 mcg -> 10 mcg | Twice daily (60 min before meals) | Ongoing | FDA label |
| SubQ (Bydureon) | 2 mg | Once weekly | Ongoing | FDA label |
Cycling
No cycling is applicable. Exenatide is prescribed as a continuous chronic therapy for type 2 diabetes. Discontinuation may lead to glycemic deterioration and weight regain.
Contraindications & Safety
- Contraindications: Personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN2), history of severe pancreatitis
- Common side effects: Nausea (most common, dose-dependent, transient — 44% with BID), vomiting, diarrhea, injection site reactions (Bydureon nodules)
- Drug interactions: Slows gastric emptying — may affect absorption of oral medications (space antibiotics, oral contraceptives by 1 hour); caution with sulfonylureas/insulin (hypoglycemia risk)
- Pregnancy/nursing: Category C; not recommended during pregnancy or lactation
- Special populations: Contraindicated in severe renal impairment (eGFR <30); use with caution in gastroparesis; no dose adjustment needed for hepatic impairment
Synergistic Combinations
- Metformin (not a peptide) + Exenatide — Complementary mechanisms: metformin suppresses hepatic glucose output, exenatide enhances insulin secretion and slows absorption
- Pramlintide — Theoretical dual-pathway approach: GLP-1 + amylin receptor agonism (basis for CagriSema concept)
Historical Significance
Exenatide holds a unique place in peptide therapeutics history. Approved in 2005, it was the first GLP-1 receptor agonist ever approved for any indication. Its discovery from Gila monster venom by John Eng (VA Medical Center, Bronx) in 1992 launched the entire GLP-1 RA drug class that now includes semaglutide, tirzepatide, dulaglutide, and liraglutide — agents that have collectively transformed the treatment of type 2 diabetes and obesity. Understanding exenatide's mechanism is foundational to understanding every subsequent GLP-1 RA.
Related Research
| PMID | Title | Year | Study Type |
|---|---|---|---|
| 28910237 | Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL) | 2017 | RCT |
| 19719703 | Exenatide efficacy and safety: a systematic review | 2009 | Systematic Review |
| 25744115 | Five-year efficacy and safety data of exenatide once weekly (DURATION-1) | 2015 | RCT (extension) |
References
- PMID 28910237 — EXSCEL cardiovascular outcomes trial
- PMID 19719703 — Exenatide efficacy/safety systematic review
- PMID 25744115 — DURATION-1 five-year data
Related
#peptide #metabolic #fda-approved #not-sold #subq